在帕金森病患者的大型在线队列中发现便秘
Adil E Bharucha1, Mohammad Ghafouri2, Revati Varma2
1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Movement disorders clinical practice
|June 20, 2025
概括
便秘在帕金森病 (PD) 中很常见,并且与更严重的运动和非运动症状有关. 这种情况表明PD患者的预后较差.
科学领域:
- 神经学 神经学
- 胃肠病学 胃肠病学
背景情况:
- 便秘是帕金森病 (PD) 经常报告的一种症状.
- 现有研究表明,便秘和PD患者的预后较差之间存在潜在联系.
研究的目的:
- 研究帕金森病中便秘和运动症状之间的关联.
- 在PD患者中检查便秘和各种非运动症状 (NMS) 之间的关系.
- 确定便秘是否预测未来运动和非运动症状的发展或恶化.
主要方法:
- 利用了福克斯洞察数据库,这是一个大规模的帕金森病研究平台.
- 对比了患有便秘和没有便秘的PD患者的基线特征.
- 评估了进展性运动症状的风险和与便秘状态相关的NMS发生率.
主要成果:
- 超过80%的参与者报告了便秘症状.
- 便秘与年龄较大,女性性别,疾病持续时间较长和并发症得分较高有显著的关联.
- 患有便秘的患者表现出更糟糕的运动症状和更高的NMS患病率,包括便失禁,消,睡眠障碍和尿急症.
- 随访分析显示,便秘增加了发生胃肠道,自主,神经精神,睡眠相关和感官NMS的风险,以及跌倒和认知障碍.
结论:
- 便秘是帕金森病的一个普遍症状.
- 便秘的存在与运动和非运动症状的严重程度密切相关.
- 便秘作为一种更严重的疾病过程和更糟糕的预后在帕金森病患者的指标.
相关概念视频
Parkinson's Disease: Overview
722
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
722
Parkinson's Disease: Treatment
391
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
391
Drugs for Treatment of Constipation-Predominant IBS
353
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
353
Chronic Bowel Disorders: Introduction
543
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
543
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
256
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
256
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
644
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
644


